找回密碼
 To register

QQ登錄

只需一步,快速開始

掃一掃,訪問微社區(qū)

打印 上一主題 下一主題

Titlebook: Direct Oral Anticoagulants; From Pharmacology to Riccardo Proietti,Ahmed AlTurki,T. Jared Bunch Book 2021 Springer Nature Switzerland AG 20

[復制鏈接]
樓主: FAD
21#
發(fā)表于 2025-3-25 05:24:40 | 只看該作者
https://doi.org/10.1007/978-981-32-9127-0thromboprophylaxis in patients with non-valvular atrial fibrillation (NVAF) and for the treatment and prevention of venous thromboembolism (VTE). In patients with multiple conditions, as in particular NVAF ones or with cancer, the contemporary administration of several drugs can cause relevant drug–
22#
發(fā)表于 2025-3-25 08:35:18 | 只看該作者
The Community Street Soccer Programr Xa inhibitors (rivaroxaban, apixaban, edoxaban, betrixaban). They have largely replaced vitamin K anticoagulants (VKAs) in clinical practice. Their overall safety profile concerning bleeding appears to be at least equivalent, if not superior, to VKAs. However, the lack of a specific reversal agent
23#
發(fā)表于 2025-3-25 12:01:28 | 只看該作者
https://doi.org/10.1007/978-1-4614-5996-5ant agents play a key role in preventing this complication. Through years, several risk stratification algorithms have been investigated, while others are still object of debate. According to current guidelines, CHA2DS2VASc score and HAS-BLED score are the ones suggested for stroke and bleeding risk
24#
發(fā)表于 2025-3-25 16:29:23 | 只看該作者
William J. Moreau,Dustin Nabhanmorrhagic events are increased in patients with kidney disease. Oral anticoagulation therapy, nowadays preferably with direct oral anticoagulants (DOACs), represents the cornerstone for ischemic stroke prevention in high-risk patients. However, all four available DOACs (dabigatran, apixaban, rivarox
25#
發(fā)表于 2025-3-25 22:12:35 | 只看該作者
26#
發(fā)表于 2025-3-26 03:46:07 | 只看該作者
Brenden J. Balcik,Aaron J. Monseauovascular (CV) risk, more and more evidences suggest a favorable prognosis in obese subjects with cardiovascular disease (CVD), a phenomenon known as “obesity paradox.” Obesity paradox has been demonstrated in various CVD including atrial fibrillation (AF) and venous thromboembolism (VTE) for which
27#
發(fā)表于 2025-3-26 06:57:18 | 只看該作者
https://doi.org/10.1007/978-3-030-36790-9thromboembolism is a leading cause of mortality, especially in patients undergoing chemotherapy. The anticoagulant strategy to be administered in these cases is particularly difficult to choose due to an altered state of coagulation that makes the balance between hypercoagulation and bleeding risk i
28#
發(fā)表于 2025-3-26 12:02:28 | 只看該作者
29#
發(fā)表于 2025-3-26 14:24:55 | 只看該作者
30#
發(fā)表于 2025-3-26 18:58:51 | 只看該作者
 關于派博傳思  派博傳思旗下網站  友情鏈接
派博傳思介紹 公司地理位置 論文服務流程 影響因子官網 吾愛論文網 大講堂 北京大學 Oxford Uni. Harvard Uni.
發(fā)展歷史沿革 期刊點評 投稿經驗總結 SCIENCEGARD IMPACTFACTOR 派博系數 清華大學 Yale Uni. Stanford Uni.
QQ|Archiver|手機版|小黑屋| 派博傳思國際 ( 京公網安備110108008328) GMT+8, 2025-10-10 17:11
Copyright © 2001-2015 派博傳思   京公網安備110108008328 版權所有 All rights reserved
快速回復 返回頂部 返回列表
从江县| 鲁甸县| 秭归县| 大余县| 乌拉特后旗| 永济市| 桐梓县| 包头市| 聂拉木县| 井冈山市| 米泉市| 施秉县| 焉耆| 泰和县| 大埔区| 望奎县| 连平县| 安泽县| 普宁市| 宝应县| 安康市| 荥经县| 台湾省| 化隆| 红桥区| 密山市| 宁国市| 桂平市| 黔西县| 城固县| 西吉县| 博野县| 阳泉市| 灌南县| 福安市| 弋阳县| 海林市| 溧阳市| 深州市| 乌苏市| 卓尼县|